scholarly journals Interactions of Pesticides with Drug Efflux Transporter P‐glycoprotein in the European Honeybee

2020 ◽  
Vol 34 (S1) ◽  
pp. 1-1
Author(s):  
Amara Pouv ◽  
Sascha Nicklisch
2008 ◽  
Vol 24 (3) ◽  
pp. 290-300 ◽  
Author(s):  
Srinivasan Senthilkumari ◽  
Thirumurthy Velpandian ◽  
Nihar R. Biswas ◽  
Narayanan Sonali ◽  
Supriyo Ghose

2020 ◽  
Vol 11 (6) ◽  
pp. 5017-5023 ◽  
Author(s):  
Tomohiro Nabekura ◽  
Tatsuya Kawasaki ◽  
Yu Kato ◽  
Kazuyoshi Kawai ◽  
Serena Fiorito ◽  
...  

Citrus phytochemical auraptene activates the drug efflux transporter P-glycoprotein gene (MDR1) promoter in human intestinal LS174T cells. Auraptene increases protein expression of P-glycoprotein. Auraptene can cause food–drug interactions.


ACS Omega ◽  
2018 ◽  
Vol 3 (2) ◽  
pp. 1621-1626 ◽  
Author(s):  
Tomohiro Nabekura ◽  
Tatsuya Kawasaki ◽  
Michi Furuta ◽  
Tomoji Kaneko ◽  
Yuichi Uwai

2016 ◽  
Vol 37 (4) ◽  
pp. 1199-1212 ◽  
Author(s):  
Vijay R More ◽  
Christopher R Campos ◽  
Rebecca A Evans ◽  
Keith D Oliver ◽  
Gary NY Chan ◽  
...  

Lipid sensor peroxisome proliferator-activated receptor alpha (PPAR- α) is the master regulator of lipid metabolism. Dietary release of endogenous free fatty acids, fibrates, and certain persistent environmental pollutants, e.g. perfluoroalkyl fire-fighting foam components, are peroxisome proliferator-activated receptor alpha ligands. Here, we define a role for peroxisome proliferator-activated receptor alpha in regulating the expression of three ATP-driven drug efflux transporters at the rat and mouse blood–brain barriers: P-glycoprotein (Abcb1), breast cancer resistance protein (Bcrp/Abcg2), and multidrug resistance-associated protein 2 (Mrp2/Abcc2). Exposing isolated rat brain capillaries to linoleic acid, clofibrate, or PKAs increased the transport activity and protein expression of the three ABC transporters. These effects were blocked by the PPAR- α antagonist, GW6471. Dosing rats with 20 mg/kg or 200 mg/kg of clofibrate decreased the brain accumulation of the P-glycoprotein substrate, verapamil, by 50% (in situ brain perfusion; effects blocked by GW6471) and increased P-glycoprotein expression and activity in capillaries ex vivo. Fasting C57Bl/6 wild-type mice for 24 h increased both serum lipids and brain capillary P-glycoprotein transport activity. Fasting did not alter P-glycoprotein activity in PPAR- α knockout mice. These results indicate that hyperlipidemia, lipid-lowering fibrates and exposure to certain fire-fighting foam components activate blood–brain barrier peroxisome proliferator-activated receptor alpha, increase drug efflux transporter expression and reduce drug delivery to the brain.


2010 ◽  
Vol 61 (3) ◽  
pp. 259-263 ◽  
Author(s):  
Tomohiro Nabekura ◽  
Takeshi Yamaki ◽  
Takashi Hiroi ◽  
Kazuyuki Ueno ◽  
Shuji Kitagawa

2015 ◽  
Vol 2015 ◽  
pp. 1-21 ◽  
Author(s):  
Famida G. Hoosain ◽  
Yahya E. Choonara ◽  
Lomas K. Tomar ◽  
Pradeep Kumar ◽  
Charu Tyagi ◽  
...  

The efficient noninvasive treatment of neurodegenerative disorders is often constrained by reduced permeation of therapeutic agents into the central nervous system (CNS). A vast majority of bioactive agents do not readily permeate into the brain tissue due to the existence of the blood-brain barrier (BBB) and the associated P-glycoprotein efflux transporter. The overexpression of the MDR1 P-glycoprotein has been related to the occurrence of multidrug resistance in CNS diseases. Various research outputs have focused on overcoming the P-glycoprotein drug efflux transporter, which mainly involve its inhibition or bypassing mechanisms. Studies into neurodegenerative disorders have shown that the P-glycoprotein efflux transporter plays a vital role in the progression of schizophrenia, with a noted increase in P-glycoprotein function among schizophrenic patients, thereby reducing therapeutic outcomes. In this review, we address the hypothesis that methods employed in overcoming P-glycoprotein in cancer and other disease states at the level of the BBB and intestine may be applied to schizophrenia drug delivery system design to improve clinical efficiency of drug therapies. In addition, the current review explores polymers and drug delivery systems capable of P-gp inhibition and modulation.


Sign in / Sign up

Export Citation Format

Share Document